The Development of Biopharmaceuticals for Autoimmune Diseases
American Journal Of Pharmacy And Pharmacology · 2025-06-30 · 6 (3) · 1-4
DOI: 10.71465/ajpp.3373 ↗At a glance
Journal article in American Journal Of Pharmacy And Pharmacology, published online on 2025-06-30. Written by Dr. Thomas Nguyen. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Biopharmaceuticals have transformed the treatment landscape for autoimmune diseases by offering targeted and effective therapeutic options. These biologically-derived agents, including monoclonal antibodies, cytokine modulators, and fusion proteins, are designed to modulate immune responses with high specificity. This article reviews the development of biopharmaceuticals in autoimmune disease therapy, highlighting key breakthroughs, clinical applications, safety considerations, and future research directions. The integration of biopharmaceuticals into treatment regimens represents a significant advancement in personalized and precision medicine.
Cite
APA
Nguyen, D. T. (2025). The Development of Biopharmaceuticals for Autoimmune Diseases. American Journal Of Pharmacy And Pharmacology, 6(3), 1-4. https://doi.org/10.71465/ajpp.3373
Vancouver
Nguyen DT. The Development of Biopharmaceuticals for Autoimmune Diseases. American Journal Of Pharmacy And Pharmacology. 2025;6(3):1-4. doi:10.71465/ajpp.3373
BibTeX
@article{Nguyen2025,
author = {Nguyen, Dr. Thomas},
title = {The Development of Biopharmaceuticals for Autoimmune Diseases},
journal = {American Journal Of Pharmacy And Pharmacology},
year = {2025},
volume = {6},
number = {3},
pages = {1--4},
doi = {10.71465/ajpp.3373}
}
EUVIMED